tbuckley/cabot-search huggingface dataset:
End-of-Life Strategies among Patients with Advanced Chronic Obstructive Pulmonary Disease
Authors: Andrea S. Gershon, Laura C. Maclagan, Jin Luo, Teresa To, Tetyana Kendzerska, Matthew B. Stanbrook, Jean Bourbeau, Jacob Etches, Shawn D. Aaron
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

The burden of advanced chronic obstructive pulmonary disease (COPD) is high globally; however, little is known about how often end-of-life strategies are used by this population.To describe trends in the use of end-of-life care strategies by people with advanced COPD in Ontario, Canada.A population-based repeated cross-sectional study examining end-of-life care strategies in individuals with advanced COPD was conducted. Annual proportions of individuals who received formal palliative care, long-term oxygen therapy, or opioids from 2004 to 2014 were determined. Results were age and sex standardized and stratified by age, sex, socioeconomic status, urban/rural residence, and immigrant status. Measurement/Main Results: There were 151,912 persons with advanced COPD in Ontario between 2004 and 2014. Use of formal palliative care services increased 1% per year from 5.3% in 2004 to 14.3% in 2014 (P value for trend < 0.001), whereas use of long-term oxygen therapy increased 1.1% per year from 26.4% in 2004 to 35.3% in 2013 (P value for trend < 0.001). The use of opioids was relatively stable (40.0% in 2004 and 41.8% in 2014; P value for trend = 0.08). Younger individuals were less likely to use formal palliative care services and long-term oxygen therapy. Males were less likely than females to receive long-term oxygen therapy and opioids.The proportion of people with advanced COPD using end-of-life strategies, although increasing, remains low. Efforts should focus on increasing access to such strategies and educating patients and providers of their benefits.
Infectious Disease Testing for Blood Transfusions
Authors: None NIH
Journal: JAMA (1995)

To provide physicians and other transfusion medicine professionals with a current consensus on infectious disease testing for blood transfusions.A nonfederal, nonadvocate, 12-member consensus panel representing the fields of hematology, infectious disease, transfusion medicine, epidemiology, and biostatistics and a public representative. In addition, 23 experts in hematology, cardiology, transfusion medicine, infectious disease, and epidemiology presented data to the consensus panel and a conference audience of 450.The literature was searched through MEDLINE and an extensive bibliography of references was provided to the panel and the conference audience. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience.The panel, answering predefined consensus questions, developed their conclusions based on the scientific evidence presented in open forum and the scientific literature.The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference.The serum alanine aminotransferase test should be discontinued as a surrogate marker for blood donors likely to transmit posttransfusion non-A, non-B hepatitis infection since specific hepatitis C antibody testing has eliminated more than 85% of these cases. Antibody to hepatitis B core antigen testing should continue as it may prevent some cases of posttransfusion hepatitis B; it may also act as a surrogate marker for human immunodeficiency virus (HIV) infection in donors and may prevent a small number of cases of transfusion-transmitted HIV infection. Syphilis testing should continue until adequate data can determine its effect on the rarity of transfusion-transmitted syphilis. Vigilant public health surveillance is critical in responding to emerging infectious disease threats to the blood supply.
Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study
Authors: Gina P. Kwon, Christina S. Gamba, Marcia L. Stefanick, Susan M. Swetter, Shufeng Li, Run Zhang Shi, Christina A. Clarke, David Feldman, Amy E. Millen, Catherine Messina, James M. Shikany, JoAnn E. Manson, Rowan T. Chlebowski, Jean Y. Tang
Journal: Journal of the American Academy of Dermatology (2018)
特应性皮炎患者体内抗体盛行,对金黄色葡萄球菌抗原作出反应:系统性评述和元分析
Authors: J. de Wit, J.E.E. Totte, F.J.M. van Buchem, S.G.M.A. Pasmans
Journal: British Journal of Dermatology (2018)

特应性皮炎(AD)是一种常见的湿疹。金黄色葡萄球菌(S.)是AD的致病因子之一,可以随各种细菌物质侵入人体。AD患者的身体免疫系统对这些物质作出反应时,可能会引起常见于AD的炎症反应。在本研究中,我们对现有文献(例如发布在医学期刊上的研究)进行了概述,总结了其中对照AD患者和健康对照组(非AD患者)得出的关于人体自身免疫系统对金黄色葡萄球菌物质(抗原)作出的免疫反应(抗体)的研究结论。科学文献从不同的数据库系统地获取。我们提取了有关多久可以在AD患者体内发现一次针对金黄色葡萄球菌的IgE型抗体(所谓的“盛行率”)的数据。由于对更多患者实施的研究被视为更具相关性,因此我们计算了加权盛行率,并且对AD患者和健康对照组之间的盛行率进行了比较。完成了研究和总体研究质量之间的差异测试,以说明结果的稳健性。我们囊括了涵盖总共2,369名患者的26份刊物。在10项研究中,还对对照组(非AD患者)进行了研究。研究质量处于中低水准。针对金黄色葡萄球菌的IgE加权盛行率分别为:葡萄球菌肠毒素(SE) A 33%、SEB 35%、中毒性休克毒素(TSST)‐1 16%。相较于健康对照组,AD患者体内针对SEA的IgE和针对SEB的IgE分别是健康对照组的8.37倍和9.37倍。针对TSST‐1的IgE未发现存在显著差异。结果说明应考虑到研究设计方面存在一些显著差异,而且研究通常规模较小。总之,AD患者与健康对照组相比,更常会出现针对金黄色葡萄球菌抗原SEA和SEB的IgE抗体反应。上述发现表明,金黄色葡萄球菌可能是AD的致病因子。
SP0003 Axspa patient with peripheral manifestations
Authors: A. Sepriano
Journal: Annals of the Rheumatic Diseases (2018)

<h3></h3> A case of a 32 year old Caucasian, female patient referred to an outpatient rheumatology clinic with a 3 month history of low back pain and a 2 week duration severe left heel pain is presented. Disease presentation, including findings on physical examination, laboratory tests and imaging are discussed, as well as their potential impact on treatment decisions. <h3>Disclosure of Interest</h3> None declared
AB0434 The influence of body mass index on the efficacy of tumour necrosis factor blocking therapy and disease activity in patients with rheumatoid arthritis
Authors: E.N. Mole, K. Zoupidou, A. Alexoudis, E. Koutsantoni, C. Sfontouris, S. Gazi
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The impact of Body Mass Index (BMI) on efficacy of TNF blocking therapy in Rheumatoid Arthritis (RA) patients and therefore on control of the disease is an important question. <h3>Objectives</h3> The aim of this study is to determine the influence of BMI on the efficacy of TNF blocking therapy in terms of disease activity in patients with RA. <h3>Methods</h3> A retrospective, observational study of 168 consecutive RA patients who received subcutaneously (SC) TNF blocking treatment (adalimumab, etanercept, golimumab and certolizumab pegol). Their follow-up data, for at least 26 weeks, and their baseline BMIs were available. The WHO definition for normal weight, overweight and obesity was applied, whereas clinical response was compared by BMI subgroups. <h3>Results</h3> The average BMI was 26.83±4.34 kg/m<sup>2</sup> and the baseline Disease Activity Score in 28 joints (DAS28 [ESR]) was high at 5.72±0.84. Mean age was 63.47±12.58 years and 135 (80.36%) were female. The median disease duration was 13.01±8.57 years. Overall, patients with normal weight responded better to treatment regimen, followed by overweight and obese subgroups. After a follow-up period of 26 weeks, the obese group had significantly higher DAS28 (ESR) and Health Assessment Questionnaire (HAQ) than either normal or overweight subgroups (3.26±0.84 <i>vs</i> 2.72±0.78 <i>vs</i> 2.81±0.82, p&lt;0.001, 0.423±0.002 <i>vs</i> 0.076±0.01 <i>vs</i> 0.178±0.01, p&lt;0.001 respectively). Furthermore, obesity was significantly associated with a decreased tendency of achieving week 26 remission, based on DAS28 (&lt;2.6) <i>p</i>:0.002 and normal HAQ (≤0.5) <i>p</i>: 0.003. <h3>Conclusions</h3> Patients with RA and higher BMIs demonstrated a diminished clinical response after 26 weeks of SC-administered TNF-blocking treatment compared with their counterparts with lower BMIs. <h3>References</h3> [1] Klaasen R1, et al. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum2011Feb;63(2):359–64. [2] Puig L1. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol2011Sep;25(9):1007–11. [3] Daïen CI1, et al. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm2014;2014:386148. [4] Schulman E1, et al. Overweight and Obesity Reduce the Likelihood of Achieving Sustained Remission in Early Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort Study. Arthritis Care Res (Hoboken)2017Nov 30. <h3>Disclosure of Interest</h3> None declared
Uncovering the dynamic relationship between Ki-67 and mitotic indices in breast cancer.
Authors: Guilherme Henrique Cantuaria, Vaishali Pannu, Padmashree C.G. Rida, Sergey Klimov, Colleen S. Austin, Josef Venable, Taylor Oakley, Josef Venable, Michelle D. Reid, Ritu Aneja
Journal: Journal of Clinical Oncology (2014)

1030 Background: The generation of intra-tumor genetic diversity and metastatic clones relies on frequent passage of cancer cells through error-prone mitoses. Thus, we postulate that low-grade tumors undergo rapid mitotic turnover to drive clonal heterogeneity, while high-grade tumors focus more on their “metastasis program
<i>Notes from the Field:</i> Contact Investigation for an Infant with Congenital Tuberculosis Infection — North Carolina, 2016
Authors: Jessica L. Rinsky, Darlene Farmer, Jessica Dixon, Jean-Marie Maillard, Thomas Young, Jason Stout, Amina Ahmed, Aaron Fleischauer, Jennifer MacFarquhar, Zack Moore
Journal: MMWR Morbidity and Mortality Weekly Report (2018)
Why Merkel Cell Cancer Is Garnering More Attention
Authors: Rebecca Voelker
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 14217: Long Term Efficacy of Atrial Based Pacing and Beta Blocker Therapy to Prevent Sudden Cardiac Death in Congenital Long Qt Syndrome
Authors: Arka Chatterjee, Harish Doppalapudi, Yung R Lau, Takumi Yamada, Hugh T McElderry, Vance J Plumb, George N Kay
Journal: Circulation (2013)

Introduction:  Conflicting data exists for congenital long QT syndrome (LQTS) treated with a combination of beta blockade and continuous pacing. High risk patients are usually treated with an implantable cardiac defibrillator (ICD) exposing them to the risk of inappropriate shocks and potentially more frequent generator replacements. Appropriate therapy also has been shown to trigger ICD storm in many cases due to increased sympathetic discharge. We sought to examine the outcome of a cohort of patients at our institution treated with the combination of a beta blocker and atrial based pacing at a higher rate than previously described.   Methods:  The long term clinical course of patients with LQTS treated with beta blockers and atrial pacing were examined to identify recurrent syncope, cardiac arrest, sudden cardiac death or the need to upgrade to a defibrillator.   Results:  A total of 30 patients with LQTS (age 26.8 ± 21.3 years; 21 females) were identified with varying presentations - syncope (n=16); torsade de pointes (n=7); cardiac arrest (n=6); family history (n=1). All patients had a pacemaker implanted and arrhythmia diagnostics turned on. Lower rate was set to a mean of 89 ± 9 bpm [ ≥ 90 (n=20); ≥80 (n=9); 70 (n=1)]. 21 patients were programmed in the AAI mode, with the rest in the DDD (n=6) or DDI (n=3) modes. Over a mean follow up of 9.7 ± 6.6 years, no patient had recurrent syncope, cardiac arrest or sudden cardiac death. None of the patients required upgrade to an ICD. 4 patients died during follow up from known unrelated causes.   Conclusion:  A combination of beta blocker therapy and atrial based pacing at a high rate is highly effective in preventing sudden death in patients with congenital LQTS. This approach may be particularly beneficial in the young population, in whom, implantation of a pacemaker rather than an ICD may enhance device longevity and avoid inappropriate ICD therapies.
SAT0589 Musculoskeletal manifestations occur predominantly in patients with older onset familial mediterranean fever
Authors: Y. Endo, T. Koga, M. Umeda, M. Ishida, Y. Fujita, S. Tsuji, A. Takatani, T. Shimizu, R. Sumiyoshi, T. Igawa, S. Fukui, A. Nishino, S.-Y. Kawashiri, N. Iwamoto, K. Ichinose, M. Tamai, H. Nakamura, T. Origuchi, K. Agematsu, A. Yachie, J. Masumoto, K. Mitiga, A. Kawakami
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Our previous nation-wide survey showed the clinical manifestations and prevalence of Japanese Familial Mediterranean Fever (FMF) patients. However, the clinical differences between young-onset FMF (YOFMF), adult-onset FMF (AOFMF), and late-onset FMF (LOFMF) have not been yet clarified. <h3>Objectives</h3> We sought to compare between the clinical profile of patients with AOFMF, LOFMF and YOFMF and to determine the clinical characteristics of them. <h3>Methods</h3> We enrolled consecutively 395 patients in 2006–2017. Mutation detection in exons 1, 2, 3, and 10 of the <i>MEFV</i> gene was performed. We defined YOFMF, AOFMF and LOFMF as the onset of FMF &lt;20, 20–39 and &amp;x2267;40 years of age, respectively. We compared clinical manifestations and mutations in <i>MEFV</i> gene among these three groups. <h3>Results</h3> The median age at the onset of YOFMF, AOFMF and LOFMF were 12.5, 28 and 51 years old respectively. A family history of FMF and a mutation in exon 10 of the <i>MEFV</i> gene were significantly more frequent in groups with younger onset ([YOFMF 28%, AOFMF 17%, LOFMF 12%; p&lt;0.01], [YOFMF 51%, AOFMF 33%, LOFMF 19%; p&lt;0.001], respectively). In the accompanying manifestations during the attacks, abdominal pain and chest pain were significantly more frequent in groups with younger onset ([YOFMF 64%, AOFMF 56%, LOFMF 30%; p&lt;0.001], [YOFMF 45%, AOFMF 33%, LOFMF 24%; p&lt;0.01], respectively), whereas arthritis and muscle pain were significantly more frequent in groups with older onset ([YOFMF 32%, AOFMF 48%, LOFMF 62%;p&lt;0.001], [YOFMF 8%, AOFMF 18%, LOFMF 26%;p&lt;0.01], respectively). There was no significantly difference in the response to colchicine among the three groups. <h3>Conclusions</h3> Our results suggest that older onset FMF had a lower percentage of mutations in exon10 of the <i>MEFV</i> gene and predominantly presented arthritis and muscle pain during the attacks. It is thus important to distinguish them from other inflammatory diseases such as gout, adult Still’s disease, and infectious arthritis. <h3>Disclosure of Interest</h3> None declared
SAT0466 Serum vitamin d deficiency is associated with active renal disease in systemic lupus erythematosus
Authors: Y.-J. Park, I.-W. Baek, K.-J. Kim, W.-U. Kim, C.-S. Cho
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> 25-hydroxyvitamin D (25(OH)D) deficiency is common in systemic lupus erythematosus (SLE) as well as chronic kidney disease. In this study, we investigated the association of 25(OH)D deficiency and renal involvement in SLE patients. <h3>Methods</h3> Two hundred seventy-two SLE patients and 138 control subjects were enrolled; 102 patients with active nephritis, 42 patients with inactive nephritis, and 128 patients with non-renal disease. Serum 25(OH)D levels were measured, and clinical and laboratory data were obtained from medical records. <h3>Results</h3> Mean serum 25(OH)D levels were significantly lower in SLE patient than control subjects (19.6 ng/ml versus 21.7 ng/ml, p=0.006). Out of 272 patients, 61.8% were vitamin D deficient (defined as &lt;20 ng/ml). Patients with active nephritis had lower serum 25(OH)D levels (16.9 ng/mL) than patients with inactive nephritis (20.2 ng/mL) and without nephritis (21.5 ng/mL) (p=0.030, p&lt;0.001), but there was no difference between the inactive nephritis and non-renal disease. Moreover, serum 25(OH)D levels were positively correlated with complement C3 (γ=0.135, p=0.026) and C4 (γ=0.159, p=0.009), but inversely with anti-dsDNA antibody level (γ=−0.156, p=0.010). Analysis of receiver operating characteristic curve for differentiating active nephritis and non-renal disease revealed an area under the curve (AUC) of 0.676, which is better than those of anti-dsDNA antibody (AUC=0.585, p=0.038) and complement C3 (AUC=0.509, p=0.001), C4 (AUC=0.538, p=0.008). <h3>Conclusions</h3> Vitamin D is deficiency is more common in SLE patients with active nephritis, and its level could be a potential marker for active renal disease in SLE. A prospective cohort study is needed to further elucidate the causal relationships over time. <h3>Disclosure of Interest</h3> None declared
Publisher Correction: Atherogenic dyslipidemia promotes autoimmune follicular helper T cell responses via IL-27
Authors: Heeju Ryu, Hoyong Lim, Garam Choi, Young-Jun Park, Minkyoung Cho, Hyeongjin Na, Chul Won Ahn, Young Chul Kim, Wan-Uk Kim, Sang-Hak Lee, Yeonseok Chung
Journal: Nature Immunology (2018)
EPEN-02. CLINICAL OUTCOME OF PEDIATRIC EPENDYMOMAS: A SINGLE INSTITUTION EXPERIENCE
Authors: Naoyuki Ohe, Takayuki Nishiwaki, Noriyuki Nakayama, Hirohito Yano, Toru Iwama
Journal: Neuro-Oncology (2018)

The standard therapy for children with ependymoma consists of maximal surgical resection followed by focal irradiation, but chemotherapy has not a role in most treatment regimens for ependymoma to date. We evaluated the curative effects for the children with ependymoma in Gifu University Hospital. Between 2002 and 2017, 9 children (6 boys and 3 girls) with median age of 6.8 years (range 2–18 years), 4 supratentorial ependymomas (WHO grade II: 3 cases, grade III: 1 case) and 5 infratentorial ependymomas (WHO grade II: 3 cases, grade III: 2 cases) were treated. Treatment protocol between 2002 and 2006, all children underwent surgery followed by focal irradiation and only children with WHO grade III ependymoma were done chemotherapy, between 2007 and 2013, all children underwent surgery followed by irradiation with/without chemotherapy. Recently, recurrent ependymoma patients underwent tumor removal followed by phoyodynamic therapy (PDT) using Talaporfin Sodium. Median progression-free survival (PFS) was 80 months. 5-year OS was 70% and 10-year OS was also 70%. The significant difference was not recognized in surgery, location, radiotherapy and chemotherapy. Maximal surgical resection and local radiotherapy are thought to be a standard therapy for the ependymoma. PDT for ependymoma have no evidence at present, but we want to accumulate cases.
LGG-39. EPIDEMIOLOGY, MANAGEMENT AND OUTCOME OF PAEDIATRIC LOW GRADE GLIOMA IN HONG KONG
Authors: Dennis TL Ku, Matthew MK Shing, Anthony Liu, C W Luk, S C Ling, Godfrey CF Chan
Journal: Neuro-Oncology (2018)

Retrospective cohort for patients age 0 to 18 years old from January 1999 to Aug 2016 diagnosed to have low grade glioma. Fifty-five patients diagnosed with pLGG with n=50 (91%) got a tissue diagnosis all showing astrocytoma WHO grade 1. Sites included cerebellum (n=29, 53%), cerebrum (n=10, 18%), brainstem (n=7, 13%), optic pathway (n=8, 15%) and spinal (n=1, 2%). Four patients (7%) have multi-focal tumours. Thirty-three (60%) patients received surgery alone and remained alive. Chemotherapy adopted including CCNU/CDDP/VCR, VCR/CPM/CDDP/VP-16, BLE/VP-16/CDDP, PCZ/CCNU/VCR, TMZ, CBDCA/VCR. Six (11%) received focal radiotherapy. One had NF-1 with thalamic lesion treated by surgery alone. One had TSC treated with mTOR inhibitor. Seven (13%) had progressive disease after chemotherapy and six remained alive. One had refractory brainstem tumour despite varies chemotherapy. The tumour had BRAF-KIAA1549 fusion and patient achieved stable disease after MEK-inhibitor (currently only 3 months). Three patients (5%) died. The first had parietal tumour at 12 years old received CCV and focal radiotherapy 54Gy, died from disease progression 5.8 years later. The second presented with diencephalic syndrome at 8 months old, received VCR/CPM/CDDP/VP-16 with stable disease, then died from status epilepticus 1.7 years later. The third had optic pathway glioma diagnosed at 2 months old, died from pneumonia 5.6 years from diagnosis. Median follow-up was 7.2 years (0.4-18). OS at 5 years was 94.1%. pLGG had excellent prognosis. Many patients treated successfully with surgery alone. New novel therapy from advanced molecular study might provide better prognosis and spare some patients from radiotherapy.
ATRT-40. IMPACT OF MOLECULAR SUBTYPES ON TREATMENT OUTCOMES IN RHABDOID TUMORS - A REPORT FROM THE RARE TUMOR CONSORTIUM
Authors: Ben Ho, Adriana Fonseca, Salma Al-Karmi, Ashley Margol, Fupan Yao, Sylvia Cheng, Ronald Grant, Jordan Handsford, Abha Gupta, Alexandre Vasiljevic, Bruce Pawel, Nada Jabado, Cynthia Hawkins, Lucie Lafay-Cousin, Alexander Judkins, Eric Bouffet, Annie Huang
Journal: Neuro-Oncology (2018)

Rhabdoid Tumors (RTs) are rare heritable cancers with bi-allelic SMARCB1/A4 alterations, arising in the brain (Atypical Teratoid/Rhabdoid Tumors/ATRTs) and in various extra-cranial locations (Malignant Rhabdoid Tumors/MRTs). Recent studies uncovered molecular sub-types of ATRTs and MRTs, however, the molecular relationship and clinico-pathologic implications of MRTs and ATRTs sub-types remain unclear. To inform clinical understanding of ATRTs and MRTs, 450/850K methylation array profiles generated from 202 ATRTs and 57 MRTs were used to define molecular categories of ATRTs/MRTs and examine their clinical significance. ATRTs segregated into 3 known molecular subgroups, group 1/SHH (n=87), group 2A/TYR (n=69), group 2B/MYC (n= 46); 13 and 44 MRTs respectively segregated with group 2A/TYR and 2B/MYC ATRTs. Median patient age was 19.1 months for group 1/SHH, 12.3 months for group 2A/TYR and 22.3 months for group 2B/MYC Rhabdoid tumors. Complete clinical information and treatment information available for 162 patients (n=125 ATRTs and n=37 MRTs), indicated only 65 patients received a combined chemo-radiation therapy. 24-month PFS was 30%,38% and 28% and the 24-month OS was 43%,48% and 43% for subgroups 1/SHH, 2A/TYR and 2B/MYC tumors respectively. MRT and ATRT comprise a biological spectrum with overlapping molecular features. Clinicopathologic analysis suggest ATRT/MRT molecular subtypes have different therapeutic response to chemo-radiotherapeutic regimens.